For many companies, rising to become part of the S&P 500 (S&P Indices:.INX) represents the pinnacle of their achievement. Given the effort and business acumen necessary to take a small business and nurture it over the years to become a large-cap giant of its industry, the few companies that successfully make the journey all involve fascinating stories of overcoming challenges and capitalizing on opportunities.
To get a sense of what’s involved in making the big leagues, let’s take a look at the four newest members of the S&P 500. With all of these companies having just joined the index earlier this year — and three of them within the past month — they should be able to give clues about what the next S&P 500 inductees might look like.
PVH Corp (NYSE:PVH)
PVH Corp (NYSE:PVH) may have an unassuming name, but the high-fashion apparel-brand company includes some of the best-known clothes-makers in the business. PVH has become one of the 25 best companies in America by leveraging the value of brands like Calvin Klein and Tommy Hilfiger, as well as the Phillips-Van Heusen brand whose initials live on in the corporate name of the company. With recent moves to consolidate its command of key branding and consistently looking for new opportunities to boost the power of its marketing and distribution network, PVH Corp (NYSE:PVH) is looking to take full advantage of worldwide growth to expand its reach.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) just joined the S&P 500 (S&P Indices:.INX) at the beginning of May, but investors have already looked beyond that to the big potential that the biotech has with its promising drugs. In particular, the failure of rival Allergan in coming up with a viable competitor to Regeneron’s Eylea treatment for macular degeneration helped push Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares up even further this month. Moreover, Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s recently announced partnership with Sanofi to test its sarilumab rheumatoid arthritis drug could potentially produce a blockbuster in the space that could unseat well-established competitor Enbrel.
Macerich Co (NYSE:MAC)
Macerich Co (NYSE:MAC) isn’t the flashiest of companies, but as a real estate investment trust specializing in shopping malls, it rewards investors with a strong dividend yield above 3% along with the promise of real-estate appreciation in its portfolio of properties. Even though it’s a newcomer to the index, Macerich Co (NYSE:MAC) will actually be just the third-smallest REIT in the S&P 500. With so many major anchor-tenant retailers suffering big issues with keeping sales up, Macerich Co (NYSE:MAC) faces some significant challenges in keeping its own revenue high. But the company has gotten through tough times before, and a general rebound in commercial real estate has helped boost the stock to new highs recently.